Shares of Cel-Sci Corporation (NYSEAMERICAN:CVM – Get Free Report) crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $1.67 and traded as high as $2.14. Cel-Sci shares last traded at $1.85, with a volume of 1,482,489 shares trading hands.
Cel-Sci Stock Up 6.5%
The firm has a market cap of $25.70 million, a PE ratio of -0.15 and a beta of 0.62. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.48 and a quick ratio of 1.42. The business has a fifty day moving average price of $1.66 and a two-hundred day moving average price of $2.25.
Institutional Investors Weigh In On Cel-Sci
A hedge fund recently raised its stake in Cel-Sci stock. Renaissance Technologies LLC lifted its stake in Cel-Sci Corporation (NYSEAMERICAN:CVM – Free Report) by 133.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,890 shares of the company’s stock after acquiring an additional 20,484 shares during the quarter. Renaissance Technologies LLC owned approximately 0.42% of Cel-Sci worth $115,000 as of its most recent filing with the Securities and Exchange Commission. 12.08% of the stock is currently owned by institutional investors.
About Cel-Sci
CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other diseases. Its research includes treatments designed to stimulate or direct the body’s immune response. The company’s lead candidate, Multikine (leukocyte interleukin, injection), has been studied as a treatment before standard therapy for certain patients with head and neck cancer. Multikine is investigational and is not an approved treatment. CEL-SCI is also developing products using its Ligand Epitope Antigen Presentation System (LEAPS) technology, which is intended to target immune responses.
Further Reading
- Five stocks we like better than Cel-Sci
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Cel-Sci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cel-Sci and related companies with MarketBeat.com's FREE daily email newsletter.
